Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of rozanolixizumab in adults with ocular myasthenia gravis
2025-524757-14-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 1 more. Planned start Aug 2026; status: authorised.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-524757-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524757-14-00.